These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 21849159)

  • 1. The MYCN oncogene and differentiation in neuroblastoma.
    Westermark UK; Wilhelm M; Frenzel A; Henriksson MA
    Semin Cancer Biol; 2011 Oct; 21(4):256-66. PubMed ID: 21849159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of mir-21, which is up-regulated during MYCN knockdown-mediated differentiation, does not prevent differentiation of neuroblastoma cells.
    Buechner J; Henriksen JR; Haug BH; Tømte E; Flaegstad T; Einvik C
    Differentiation; 2011 Jan; 81(1):25-34. PubMed ID: 20980091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
    Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
    Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis.
    Chen Y; Stallings RL
    Cancer Res; 2007 Feb; 67(3):976-83. PubMed ID: 17283129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study.
    Wang LL; Teshiba R; Ikegaki N; Tang XX; Naranjo A; London WB; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Seeger RC; Asgharzadeh S; Shimada H
    Br J Cancer; 2015 Jun; 113(1):57-63. PubMed ID: 26035700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells.
    Kang JH; Rychahou PG; Ishola TA; Qiao J; Evers BM; Chung DH
    Biochem Biophys Res Commun; 2006 Dec; 351(1):192-7. PubMed ID: 17055458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
    Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
    Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroblastoma and MYCN.
    Huang M; Weiss WA
    Cold Spring Harb Perspect Med; 2013 Oct; 3(10):a014415. PubMed ID: 24086065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conditional expression of retrovirally delivered anti-MYCN shRNA as an in vitro model system to study neuronal differentiation in MYCN-amplified neuroblastoma.
    Henriksen JR; Haug BH; Buechner J; Tømte E; Løkke C; Flaegstad T; Einvik C
    BMC Dev Biol; 2011 Jan; 11():1. PubMed ID: 21194500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma.
    Selmi A; de Saint-Jean M; Jallas AC; Garin E; Hogarty MD; Bénard J; Puisieux A; Marabelle A; Valsesia-Wittmann S
    Cancer Lett; 2015 Feb; 357(1):412-418. PubMed ID: 25475555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis.
    Slack A; Lozano G; Shohet JM
    Cancer Lett; 2005 Oct; 228(1-2):21-7. PubMed ID: 15927364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of Nuclear Hormone Receptors by MYCN-Driven miRNAs Impacts Neural Differentiation and Survival in Neuroblastoma Patients.
    Ribeiro D; Klarqvist MDR; Westermark UK; Oliynyk G; Dzieran J; Kock A; Savatier Banares C; Hertwig F; Johnsen JI; Fischer M; Kogner P; Lovén J; Arsenian Henriksson M
    Cell Rep; 2016 Jul; 16(4):979-993. PubMed ID: 27396325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells.
    Schulte JH; Lindner S; Bohrer A; Maurer J; De Preter K; Lefever S; Heukamp L; Schulte S; Molenaar J; Versteeg R; Thor T; Künkele A; Vandesompele J; Speleman F; Schorle H; Eggert A; Schramm A
    Oncogene; 2013 Feb; 32(8):1059-65. PubMed ID: 22484425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The MYCN enigma: significance of MYCN expression in neuroblastoma.
    Tang XX; Zhao H; Kung B; Kim DY; Hicks SL; Cohn SL; Cheung NK; Seeger RC; Evans AE; Ikegaki N
    Cancer Res; 2006 Mar; 66(5):2826-33. PubMed ID: 16510605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wnt Signalling Drives Context-Dependent Differentiation or Proliferation in Neuroblastoma.
    Szemes M; Greenhough A; Melegh Z; Malik S; Yuksel A; Catchpoole D; Gallacher K; Kollareddy M; Park JH; Malik K
    Neoplasia; 2018 Apr; 20(4):335-350. PubMed ID: 29505958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of NLRR3 orphan receptor gene is negatively regulated by MYCN and Miz-1, and its downregulation is associated with unfavorable outcome in neuroblastoma.
    Akter J; Takatori A; Hossain MS; Ozaki T; Nakazawa A; Ohira M; Suenaga Y; Nakagawara A
    Clin Cancer Res; 2011 Nov; 17(21):6681-92. PubMed ID: 21908575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification.
    Valentijn LJ; Koster J; Haneveld F; Aissa RA; van Sluis P; Broekmans ME; Molenaar JJ; van Nes J; Versteeg R
    Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19190-5. PubMed ID: 23091029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification.
    Liu X; Mazanek P; Dam V; Wang Q; Zhao H; Guo R; Jagannathan J; Cnaan A; Maris JM; Hogarty MD
    Oncogene; 2008 Feb; 27(10):1478-88. PubMed ID: 17724465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MYCN oncoprotein targets and their therapeutic potential.
    Bell E; Chen L; Liu T; Marshall GM; Lunec J; Tweddle DA
    Cancer Lett; 2010 Jul; 293(2):144-57. PubMed ID: 20153925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasoactive intestinal peptide decreases MYCN expression and synergizes with retinoic acid in a human MYCN-amplified neuroblastoma cell line.
    Chevrier L; Meunier AC; Cochaud S; Muller JM; Chadéneau C
    Int J Oncol; 2008 Nov; 33(5):1081-9. PubMed ID: 18949372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.